Thermo-sensitive mitochondrial trifunctional protein deficiency presenting with episodic myopathy.
Marit SchwantjeMerel S EbberinkMirjam DoolaardJos P N RuiterSabine A FuchsNiklas DarinCarola Hedberg-OldforsLuc RégalLaura Donker KaatHidde H HuidekoperSimon OlpinDuncan ColeStuart J MoatGepke VisserSacha FerdinandussePublished in: Journal of inherited metabolic disease (2022)
Mitochondrial trifunctional protein (MTP) is involved in long-chain fatty acid β-oxidation (lcFAO). Deficiency of one or more of the enzyme activities as catalyzed by MTP causes generalized MTP deficiency (MTPD), long-chain hydroxyacyl-CoA dehydrogenase deficiency (LCHADD), or long-chain ketoacyl-CoA thiolase deficiency (LCKATD). When genetic variants result in thermo-sensitive enzymes, increased body temperature (e.g. fever) can reduce enzyme activity and be a risk factor for clinical decompensation. This is the first description of five patients with a thermo-sensitive MTP deficiency. Clinical and genetic information was obtained from clinical files. Measurement of LCHAD and LCKAT activities, lcFAO-flux studies and palmitate loading tests were performed in skin fibroblasts cultured at 37°C and 40°C. In all patients (four MTPD, one LCKATD), disease manifested during childhood (manifestation age: 2-10 years) with myopathic symptoms triggered by fever or exercise. In four patients, signs of retinopathy or neuropathy were present. Plasma long-chain acylcarnitines were normal or slightly increased. HADHB variants were identified (at age: 6-18 years) by whole exome sequencing or gene panel analyses. At 37°C, LCHAD and LCKAT activities were mildly impaired and lcFAO-fluxes were normal. Remarkably, enzyme activities and lcFAO-fluxes were markedly diminished at 40°C. Preventive (dietary) measures improved symptoms for most. In conclusion, all patients with thermo-sensitive MTP deficiency had a long diagnostic trajectory and both genetic and enzymatic testing were required for diagnosis. The frequent absence of characteristic acylcarnitine abnormalities poses a risk for a diagnostic delay. Given the positive treatment effects, upfront genetic screening may be beneficial to enhance early recognition.
Keyphrases
- end stage renal disease
- replacement therapy
- fatty acid
- copy number
- chronic kidney disease
- genome wide
- ejection fraction
- oxidative stress
- prognostic factors
- peritoneal dialysis
- hydrogen peroxide
- healthcare
- patient reported outcomes
- endothelial cells
- dna methylation
- transcription factor
- nitric oxide
- body composition
- patient reported
- sleep quality
- extracellular matrix
- duchenne muscular dystrophy
- childhood cancer